The most frequent adverse event reported in the EPHESUS study was hyperkalemia with an incidence rate of 3.4% for eplerenone, respectively.
Adverse events reported as follows are those with suspected relationship to treatment. Adverse events are listed by body system and absolute frequency. (See Table 2.)

View ADR Reporting Link